HWM
NPCE icon

HighMark Wealth Management’s Neuropace NPCE Stock Holding History

HighMark Wealth Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$828K Hold
63,000
– – 0.34% 37
2025
Q4 		$973K Hold
63,000
– – 0.4% 36
2025
Q3 		$650K Hold
63,000
– – 0.29% 43
2025
Q2 		$702K Buy
63,000
+60,000
+2,000% +$750K 0.34% 40
2025
Q1 		$36.9K Hold
3,000
– – 0.02% 151
2024
Q4 		$33.6K Hold
3,000
– – 0.02% 159
2024
Q3 		$20.9K Buy
+3,000
New +$21.9K 0.01% 202

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

HighMark Wealth Management's NPCE Position: Q1 2026 in Review

HighMark Wealth Management held its Neuropace (NPCE) position steady in Q1 2026 at 63,000 shares worth $828K. The position accounts for 0.34% of the portfolio, ranked #37.

HighMark Wealth Management first reported a position in NPCE in Q3 2024 and has held it in 7 quarters since. The position peaked at $973K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • HighMark Wealth Management held 63,000 shares of Neuropace worth $828K as of Q1 2026.
  • HighMark Wealth Management left its Neuropace share count unchanged in Q1 2026.
  • Neuropace made up 0.34% of HighMark Wealth Management's portfolio in Q1 2026, its #37 holding.
  • HighMark Wealth Management first reported a position in Neuropace in Q3 2024 and has held it in 7 quarters since.
  • HighMark Wealth Management's Neuropace position peaked at $973K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.